CSF1R and plasma cell myeloma: Furthermore, targeting CSF‐1R has been proven effective on haematopoietic malignancies, such as multiple myeloma, chronic lymphocytic leukaemia (CLL) and a subset of AML.19, 20, 21, 22, 23